MyPepFinder
Research Peptide

FOXO4-DRI

FOXO4-DRI research profile placeholder. Compare providers, review literature notes, and explore related goals.

★★★★★4.5(120 reviews)◆ Highly Researched
  • Research
  • Educational
Compare Providers

  • GLP-1

    Slows gastric emptying and reduces appetite signals.

  • GIP

    Supports insulin response and metabolic efficiency.

  • Glucagon

    Increases energy expenditure and fat oxidation.

What is FOXO4-DRI?

Retatrutide is an investigational triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. It has been studied as a once-weekly subcutaneous injection in Phase 2 and Phase 3 trials, with doses ranging from 1 mg to 12 mg.

  • Type

    Peptide

  • Starting Dose

    2 mg weekly

  • Max Studied

    12 mg weekly

  • Development

    Phase 3 Trials

How It Works

FOXO4-DRI engages multiple pathways that together support appetite control, metabolic efficiency, and fat oxidation.

GLP-1 Agonist

  • ✓Reduces hunger cues
  • ✓Slows gastric emptying
  • ✓Improves glycemic control

GIP Agonist

  • ✓Enhances insulin response
  • ✓Supports nutrient partitioning
  • ✓Complements GLP-1 effects

Glucagon Agonist

  • ✓Raises energy expenditure
  • ✓Increases fat oxidation
  • ✓Supports metabolic rate

Result

Reduced Calorie Intake

Increased Fat Burning

Significant Weight Loss

Expected Results Over Time

Trajectory modeling for this peptide focuses on research signals rather than weight-loss curves. See comparison and research sections below.

How FOXO4-DRI Compares

FeatureRetatrutideTirzepatideSemaglutide
Receptor ActivityGIP + GLP-1 + glucagonGIP + GLP-1GLP-1
Typical FrequencyWeeklyWeeklyWeekly
Regulatory StatusInvestigationalFDA approved (certain indications)FDA approved (certain indications)
Phase 2 avg. loss (top dose)24.2% @ 48 wks——

Side Effects

Commonly discussed effects in research summaries include mild gastrointestinal symptoms (nausea, reduced appetite). Always follow a qualified clinician's protocol. This page is educational only.

Dosage

Research protocols often use once-weekly subcutaneous administration with gradual titration. Use the Dosage Calculator to explore reconstitution math for your vial size.

Stay updated on the latest peptide research

New studies and guides delivered to your inbox.